# 2026-13821: DEA Moves to Ban Gas-Station Antidepressant

2026-13821, Schedules of Controlled Substances: Placement of Tianeptine in Schedule I, is a Federal Register proposed rule from Justice Department, Drug Enforcement Administration published 2026-07-08, effective Comments must be submitted electronically or postmarked on or before August 7, 2026. The electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period.; PRIA reads it as touching household money (as of 2026-07-15).

- Canonical: https://policyrisk.com/federal-register/2026-13821
- As of: 2026-07-15
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-13821
- Title: Schedules of Controlled Substances: Placement of Tianeptine in Schedule I
- Type: Proposed Rule
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 91 FR 42150
- Published: 2026-07-08
- Effective: Comments must be submitted electronically or postmarked on or before August 7, 2026. The electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period.
- Comments close: 2026-08-07
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-07-15

## In one line

DEA Moves to Ban Gas-Station Antidepressant

## Summary

The DEA wants to put tianeptine, a drug with potential risks, into Schedule I, meaning it’ll be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or uses tianeptine, bringing strict rules and penalties. You’ve got until August 7, 2026, to share your thoughts before the new rules could kick in.

## Abstract

The Drug Enforcement Administration proposes placing the substance tianeptine (7-[(3-chloro-6,11-dihydro-6-methyl-5,5- dioxidodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, salts, and salts of isomers, esters, and ethers is possible, in schedule I of the Controlled Substances Act. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle tianeptine.

## Effects PRIA read

- Tianeptine Proposed for Schedule I: cost, high. The DEA proposes to place tianeptine in Schedule I, which would subject anyone who handles or uses tianeptine to the strict controls that apply to the most tightly regulated drugs. If finalized, handling tianeptine (manufacture, distribution, research, import/export, or possession) would trigger ad…
- New Registration and Compliance Duties: cost, medium. Anyone who manufactures, distributes, imports, exports, researches, or otherwise handles tianeptine would need to register with DEA and comply with Schedule I rules. Required controls include DEA registration, security and screening requirements, labeling and packaging rules, quotas for manufacture…
- Research Continuation Window: 90 Days: mixed, low. If finalized, researchers already registered to conduct research with another Schedule I substance may continue research on tianeptine only if they submit a completed application for registration or modification no later than 90 calendar days after the date the final rule takes effect. Continued re…
- Surrender or Dispose Stocks If Not Registered: cost, medium. Persons unwilling or unable to obtain a Schedule I registration must surrender or transfer all tianeptine stocks to a DEA-registered person before the effective date of the final scheduling action. Any required disposal must follow 21 CFR part 1317 and other applicable laws.
- Retail Sales and Possession Made Unlawful: cost, high. Retail sales of Schedule I controlled substances to the general public are not allowed, and possession of any quantity of tianeptine in a manner not authorized by the Controlled Substances Act would be unlawful and subject to prosecution. Persons who handle tianeptine without authorization may face…

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2026-13821 on federalregister.gov](https://www.federalregister.gov/documents/2026/07/08/2026-13821/schedules-of-controlled-substances-placement-of-tianeptine-in-schedule-i)
- [2026-13821 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-07-08/pdf/2026-13821.pdf)

## Related
- [Previous: 2026-13809, Fisheries of the Northeastern United States; Omnibus Management Flexibility Ame…](https://policyrisk.com/federal-register/2026-13809)
- [Next: C1-2026-12542, Naturalization Application Fee Adjustments](https://policyrisk.com/federal-register/C1-2026-12542)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-13821 (as of 2026-07-15).
